| 922.5 -7.05 (-0.76%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1121.83 | 1-year : | 1182.01 |
| Resists | First : | 960.47 | Second : | 1012 |
| Pivot price | 923.26  |
|||
| Supports | First : | 877.1 | Second : | 729.75 |
| MAs | MA(5) : | 940.07 |
MA(20) : | 921.6 |
| MA(100) : | 1017.24 |
MA(250) : | 876.32 |
|
| MACD | MACD : | -12.1 |
Signal : | -17.4 |
| %K %D | K(14,3) : | 53.6 |
D(3) : | 63.6 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 1132.06 | Low : | 620.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LLY ] has closed above bottom band by 49.2%. Bollinger Bands are 18.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 941.93 - 947.59 | 947.59 - 951.8 |
| Low: | 901.59 - 909.06 | 909.06 - 914.61 |
| Close: | 912.69 - 923.72 | 923.72 - 931.91 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Tue, 14 Apr 2026
LLY Stock To $2,000? - Forbes
Tue, 14 Apr 2026
Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Omada Health, Inc. (OMDA) and Eli Lilly & Co (LLY) - The Globe and Mail
Mon, 13 Apr 2026
How Eli Lilly Stock Rises To $2,000 - Trefis
Mon, 13 Apr 2026
Eli Lilly Stock (LLY) Gets Shot in the Arm from New Leukemia Drug - TipRanks
Mon, 13 Apr 2026
Even After Shedding Some Weight, Eli Lilly and Company Isn't Prime For Upgrade (NYSE:LLY) - Seeking Alpha
Mon, 13 Apr 2026
Eli Lilly & Co (NYSE:LLY) Presents a Prime Case for Affordable Growth Investing - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 893 (M) |
| Shares Float | 891 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 84.6 (%) |
| Shares Short | 6,870 (K) |
| Shares Short P.Month | 6,380 (K) |
| EPS | 22.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.65 |
| Profit Margin | 31.6 % |
| Operating Margin | 44.9 % |
| Return on Assets (ttm) | 19.4 % |
| Return on Equity (ttm) | 101.1 % |
| Qtrly Rev. Growth | 42.5 % |
| Gross Profit (p.s.) | 60.59 |
| Sales Per Share | 72.96 |
| EBITDA (p.s.) | 35.47 |
| Qtrly Earnings Growth | 51.4 % |
| Operating Cash Flow | 16,810 (M) |
| Levered Free Cash Flow | 1,950 (M) |
| PE Ratio | 40.24 |
| PEG Ratio | 0 |
| Price to Book value | 31.1 |
| Price to Sales | 12.64 |
| Price to Cash Flow | 49.02 |
| Dividend | 1.73 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|